Response to Editor: Commentary on "Influence of Tumor Cavitation on Assessing the Clinical Benefit of Anti-PD1 or PD-L1 Inhibitors in Advanced Lung Squamous Cell Carcinoma"

被引：0
|
作者：
Chen, Qin [1 ,2 ,3 ]
Wang, Xinyue [1 ,2 ]
Jiang, Richeng [1 ,2 ,4 ,5 ]
机构：
[1] Tianjin Med Univ, Tianjin Canc Inst & Hosp, Tianjin Lung Canc Ctr, Dept Thorac Oncol, Tianjin, Peoples R China
[2] Tianjin Med Univ, Tianjin Canc Inst & Hosp, Natl Clin Res Ctr Canc, Tianjin Key Lab Canc Prevent & Therapy, Tianjin, Peoples R China
[3] Tianjin Chest Hosp, Dept Resp & Crit Med, Tianjin, Peoples R China
[4] Tianjin Canc Hosp, Airport Hosp, Canc Precise Diag Ctr, Tianjin, Peoples R China
[5] Tianjin Med Univ Canc Inst & Hosp, Ctr Precis Canc Med & Translat Res, Tianjin, Peoples R China
来源：
CLINICAL LUNG CANCER | 2024年 / 25卷 / 08期
基金：
中国国家自然科学基金;
关键词：
THERAPY; MECHANISM;
D O I：
10.1016/j.clc.2024.08.013
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：e479 / e481
页数：3
相关论文
共 50 条
  • [31] The efficacy of PD-1/PD-L1 inhibitors in advanced squamous-cell lung cancer: a meta-analysis of 3112 patients
    Chen, Rui-Lian
    Zhou, Jing-Xu
    Cao, Yang
    Li, Sui-Hui
    Li, Yong-Hao
    Jiang, Mei
    Lu, Dong-Yan
    Li, Peng
    Lin, Li-Zhu
    IMMUNOTHERAPY, 2019, 11 (17) : 1481 - 1490
  • [32] Influence of PD-1/PD-L1 on immune microenvironment in oral leukoplakia and oral squamous cell carcinoma
    Xu, Shuang-Bo
    Wang, Meng-Yao
    Shi, Xin-Zhan
    Wang, Qiong
    Yu, Miao
    Zhang, Wei
    Xu, Xiao-Hui
    Liu, Lai-Kui
    ORAL DISEASES, 2023, 29 (08) : 3268 - 3277
  • [33] Case report: A lung squamous cell carcinoma patient with a rare EGFR G719X mutation and high PD-L1 expression showed a good response to anti-PD1 therapy
    Zhu, Zhen-feng
    Bao, Xu-xia
    Shi, Hong-yan
    Gu, Xi-xi
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [34] Clinical and molecular characteristics associated with response to therapeutic PD-1/PD-L1 inhibition in advanced Merkel cell carcinoma
    Spassova, Ivelina
    Ugurel, Selma
    Kubat, Linda
    Zimmer, Lisa
    Terheyden, Patrick
    Mohr, Annalena
    Andtback, Hannah Bjorn
    Villabona, Lisa
    Leiter, Ulrike
    Eigentler, Thomas
    Loquai, Carmen
    Hassel, Jessica C.
    Gambichler, Thilo
    Haferkamp, Sebastian
    Mohr, Peter
    Pfoehler, Claudia
    Heinzerling, Lucie
    Gutzmer, Ralf
    Utikal, Jochen S.
    Horny, Kai
    Schildhaus, Hans-Ulrich
    Habermann, Daniel
    Hoffmann, Daniel
    Schadendorf, Dirk
    Becker, Juergen Christian
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (01)
  • [35] Expression of PD-1/PD-L1 in head and neck squamous cell carcinoma and its clinical significance
    Chen, Shu-Wei
    Li, Si-Hao
    Shi, Ding-Bo
    Jiang, Wen-Mei
    Song, Ming
    Yang, An-Kui
    Li, Yu-Dong
    Bei, Jin-Xin
    Chen, Wen-Kuan
    Zhang, Quan
    INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, 2019, 34 (04): : 398 - 405
  • [36] Pretreatment eosinophil counts (PEC) in metastatic urothelial carcinoma (mUC) treated with anti-PD1/PD-L1 checkpoint inhibitors (CPI).
    Mota, Jose Mauricio
    Teo, Min Yuen
    Whiting, Karissa
    Ostrovnaya, Irina
    Li, Han
    Lee, Chung-Han
    Funt, Samuel Aaron
    Callahan, Margaret K.
    Iyer, Gopa
    Bajorin, Dean F.
    Rosenberg, Jonathan E.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [37] Datasets for gene expression profiles of head and neck squamous cell carcinoma and lung cancer treated or not by PD1/PD-L1 inhibitors
    Foy, Jean-Philippe
    Karabajakian, Andy
    Ortiz-Cuaran, Sandra
    Boussageon, Maxime
    Michon, Lucas
    Bouaoud, Jebrane
    Fekiri, Dorssafe
    Robert, Marie
    Baffert, Kim-Arthur
    Herve, Genevieve
    Quilhot, Pauline
    Attignon, Valery
    Girod, Angelique
    Chaine, Andre
    Benassarou, Mourad
    Zrounba, Philippe
    Caux, Christophe
    Ghiringhelli, Francois
    Lantuejoul, Sylvie
    Crozes, Carole
    Brocheriou, Isabelle
    Perol, Maurice
    Fayette, Jerome
    Bertolus, Chloe
    Saintigny, Pierre
    DATA IN BRIEF, 2022, 44
  • [38] PD-L1 expression in squamous cell lung carcinoma in small biopsy specimens
    Dzambas, J.
    Aleksic, I.
    VIRCHOWS ARCHIV, 2021, 479 (SUPPL 1) : S52 - S53
  • [39] The Expression of PD-L1 Protein as a Prognostic Factor in Lung Squamous Cell Carcinoma
    Takada, K.
    Okamoto, T.
    Toyokawa, G.
    Kozuma, Y.
    Matsubara, T.
    Haratake, N.
    Akamine, T.
    Takamori, S.
    Katsura, M.
    Shoji, F.
    Oda, Y.
    Maehara, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1994 - S1994
  • [40] Model combining genomic and clinical factors to predict clinical benefit from PD1/PD-L1 inhibitors for advanced UC
    Nassar, Amin
    Mouw, Kent William
    Liu, Chia-Jen
    Lundgren, Kevin
    Van Allen, Eliezer Mendel
    Harshman, Lauren Christine
    Pomerantz, Mark
    Preston, Mark A.
    Wei, Xiao X.
    McGregor, Bradley Alexander
    Choudhury, Atish Dipankar
    Bellmunt, Joaquim
    Choueiri, Toni K.
    Kwiatkowski, David J.
    Sonpavde, Guru
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
12345